REAL-WORLD UTILIZATION AND EFFICACY OF BIOEQUIVALENT GENERIC LETERMOVIR PROPHYLAXIS IN ALLOGENEIC HSCT RECIPIENTS: PEDIATRIC SUBGROUP ANALYSIS FROM DEFENDER STUDY (EBMT 2026) - Mar 14, 2026 - Abstract #B150; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "Pre-emptive therapy was required in 13 patients (12.87%), primarily ganciclovir (10.89%) and cidofovir (1.98%). Letermovir prophylaxis demonstrated acceptable efficacy and excellent tolerability in pediatric allo-HSCT recipients, with low adverse event rates and high completion rates. Real-world data support letermovir use in pediatric transplant populations and highlight the need for individualized dosing strategies."
Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Pediatrics • Sickle Cell Disease
|
|
Santanu Sen1; Gaurav Kharya2; Rajat Bhattacharyya3; Kasi Viswanathan4; Sameer Ramesh Melinkeri5; Chintan Vyas6; Nataraj KS7; Vaibhav Chadha2; Garima Nirmal2; Anusree Prabhakaran5; Suyash Bharat8
|